Literature DB >> 21742399

The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance.

Jianjun Lan1, Xiaoni Chen, Xiaoping Chen, Si Wang, Xin Zhang, Kai Wu, Sen He, Yong Peng, Lingyun Jiang, Longxin Li, Liyan Wan.   

Abstract

OBJECTIVE: To investigate the correlation between serum visfatin and insulin resistance (IR) in non-diabetic essential hypertensive (EH) patients with and without IR, and to evaluate the effect of antihypertensive treatment on serum visfatin and IR in these patients.
METHODS: A total of 81 non-diabetic EH patients, including 54 with IR and 27 without IR, were enrolled. After two weeks wash-out, patients with IR were randomly assigned to telmisartan (group T) or amlodipine (group A) for 6 months. Blood samples were taken before and after treatment for measurement of routine biochemical parameters, visfatin and insulin resistance (measured by HOMA-IR).
RESULTS: Visfatin was independently correlated with HOMA-IR (r=0.845, P=0.000). After 6 months of treatment, both drugs lowered HOMA-IR, more significantly so in group T than group A (P=0.010). Serum visfatin levels increased in group T but decreased in group A.
CONCLUSION: Serum visfatin levels were higher in non-diabetic EH patients with IR compared with those without IR. Visfatin is independently correlated with HOMA-IR. Telmisartan lowers HOMA-IR to a greater extent than amlodipine. Interestingly, serum visfatin increased with telmisartan yet decreased with amlodipine treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21742399     DOI: 10.1016/j.diabres.2011.05.039

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  2 in total

1.  The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.

Authors:  V A Belo; M R Luizon; R Lacchini; J A Miranda; C M M Lanna; D C Souza-Costa; J E Tanus-Santos
Journal:  Int J Obes (Lond)       Date:  2013-09-12       Impact factor: 5.095

2.  Serum visfatin levels, adiposity and glucose metabolism in obese adolescents.

Authors:  Derya Taşkesen; Birgül Kirel; Tercan Us
Journal:  J Clin Res Pediatr Endocrinol       Date:  2012-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.